AIM:To investigate the potential role of Active Chinese mistletoe lectin-55 (ACML-55) in tumor immune surveillance. METHODS: In this study, an experimental model was established by hypodermic inoculating the colon can...AIM:To investigate the potential role of Active Chinese mistletoe lectin-55 (ACML-55) in tumor immune surveillance. METHODS: In this study, an experimental model was established by hypodermic inoculating the colon cancer cell line CT26 (5 × 105 cells) into BALB/c mice. The experimental treatment was orally administered with ACML-55 or PBS, followed by the inoculation of colon cancer cell line CT26. Intracellular cytokine staining was used to detect IFN-γ production by tumor antigen specific CD8+ T cells. FACS analysis was employed to profi le composition and activation of CD4+, CD8+, γδ T and NK cells. RESULTS: Our results showed, compared to PBS treated mice, ACML-55 treatment signifi cantly delayed colon cancer development in colon cancer -bearingBalb/c mice in vivo. Treatment with ACML-55 enhanced both Ag specifi c activation and proliferation of CD4+ and CD8+ T cells, and increased the number of tumor Ag specific CD8+ T cells. It was more important to increase the frequency of tumor Ag specific IFN-γ producing-CD8+ T cells. Interestingly, ACML-55 treatment also showed increased cell number of NK, and γδT cells, indicating the role of ACML-55 in activation of innate lymphocytes. CONCLUSION: Our results demonstrate that ACML-55 therapy can enhance function in immune surveillance in colon cancer-bearing mice through regulating both innate and adaptive immune responses.展开更多
槲寄生属半寄生类植物,主要分布于欧洲及东亚,中国、韩国和日本很早以前就将其作为治疗用药。自上世纪二十年代,欧洲槲寄生提取物因具有免疫调节、抑制细胞生长/细胞毒素和稳定 DNA 活性的作用,在欧洲被广泛应用于癌症的辅助治疗。对于...槲寄生属半寄生类植物,主要分布于欧洲及东亚,中国、韩国和日本很早以前就将其作为治疗用药。自上世纪二十年代,欧洲槲寄生提取物因具有免疫调节、抑制细胞生长/细胞毒素和稳定 DNA 活性的作用,在欧洲被广泛应用于癌症的辅助治疗。对于槲寄生,其主要生物活性是糖粘合蛋白,槲寄生外源凝集素类和名为粘毒素的微蛋白。槲寄生外源凝集素类是毒性植物血凝素,糖和复合糖类(包括半乳糖和/或 N-乙酰半乳糖胺)家族中的成员。活体内、外实验证实,植物体内分离出的槲寄生植物血凝素与重组合成的相比,在槲寄生提取物中起着更重要的生物活性作用。实验提示:甙类,多糖,胺类等其他成份也有抗癌活性。目前,在欧洲,关于抗癌治疗中是使用纯植物提取物还是植物血凝素的单一成份这一原则问题,包括使用野生植物凝血素还是重组的,正在讨论中。而商业性槲哥生的制备、鉴定、标准化及其生物活性测定也在讨论中。展开更多
基金The National Natural Science Foundation of China,No.30471593 and No. 30670939the Shanghai Leading Academic Discipline Project,No.T0206+1 种基金the Shanghai Commission of Science and Technology,No.07JC14033the Shanghai Institute of Immunology Project,No.07-A02
文摘AIM:To investigate the potential role of Active Chinese mistletoe lectin-55 (ACML-55) in tumor immune surveillance. METHODS: In this study, an experimental model was established by hypodermic inoculating the colon cancer cell line CT26 (5 × 105 cells) into BALB/c mice. The experimental treatment was orally administered with ACML-55 or PBS, followed by the inoculation of colon cancer cell line CT26. Intracellular cytokine staining was used to detect IFN-γ production by tumor antigen specific CD8+ T cells. FACS analysis was employed to profi le composition and activation of CD4+, CD8+, γδ T and NK cells. RESULTS: Our results showed, compared to PBS treated mice, ACML-55 treatment signifi cantly delayed colon cancer development in colon cancer -bearingBalb/c mice in vivo. Treatment with ACML-55 enhanced both Ag specifi c activation and proliferation of CD4+ and CD8+ T cells, and increased the number of tumor Ag specific CD8+ T cells. It was more important to increase the frequency of tumor Ag specific IFN-γ producing-CD8+ T cells. Interestingly, ACML-55 treatment also showed increased cell number of NK, and γδT cells, indicating the role of ACML-55 in activation of innate lymphocytes. CONCLUSION: Our results demonstrate that ACML-55 therapy can enhance function in immune surveillance in colon cancer-bearing mice through regulating both innate and adaptive immune responses.
文摘槲寄生属半寄生类植物,主要分布于欧洲及东亚,中国、韩国和日本很早以前就将其作为治疗用药。自上世纪二十年代,欧洲槲寄生提取物因具有免疫调节、抑制细胞生长/细胞毒素和稳定 DNA 活性的作用,在欧洲被广泛应用于癌症的辅助治疗。对于槲寄生,其主要生物活性是糖粘合蛋白,槲寄生外源凝集素类和名为粘毒素的微蛋白。槲寄生外源凝集素类是毒性植物血凝素,糖和复合糖类(包括半乳糖和/或 N-乙酰半乳糖胺)家族中的成员。活体内、外实验证实,植物体内分离出的槲寄生植物血凝素与重组合成的相比,在槲寄生提取物中起着更重要的生物活性作用。实验提示:甙类,多糖,胺类等其他成份也有抗癌活性。目前,在欧洲,关于抗癌治疗中是使用纯植物提取物还是植物血凝素的单一成份这一原则问题,包括使用野生植物凝血素还是重组的,正在讨论中。而商业性槲哥生的制备、鉴定、标准化及其生物活性测定也在讨论中。
